VERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer

Veru will seek an FDA pre-IND meeting in Q4 2026 after preclinical data showed sabizabulin remains potent in daraxonrasib-resistant pancreatic cancer cells.